Oncology

We've compiled a list of 5 clinical trials with expected data readouts in 2025 that are worth keeping an eye on.

Review top news and interview highlights from the week ending January 24, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The holds are related to a GMP compliance issue at a third-party manufacturing facility.

Review top news and interview highlights from the week ending January 17, 2025.

The CGTLive® team highlights 5 therapeutics with PDUFA dates or other FDA actions likely in 2025.

The CRL was related inspection of a third-party manufacturer rather than any efficacy or safety concerns regarding the product itself.

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.

The multicenter trial is open to patients with forms of r/r B-NHL including DLBCL, FL, MCL, and MZL.

Review top news and interview highlights from the week ending January 10, 2025.

According to EsoBiotec, this is the first time a patient has been treated with an in vivo BCMA-directed CAR-T therapy in a clinical trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

In 2024, CGTLive spoke with experts at various medical conferences to seek their insight on the data they presented and more.

Review top news and interview highlights from the weeks ending December 27, 2024, and January 3, 2025.

Take a look what stood out as pillars of progress and success from all of CGTLive's most popular oncology stories in 2024.

In 2024, CGTLIve spoke with experts outside the context of the conference cycle to seek their insight on company announcements, pipeline therapies, and disease awareness, among other topics.

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed 5-year follow-up data from the TRANSCEND-NHL-001 clinical trial.

Review top news and interview highlights from the week ending December 20, 2024.

Natural killer cells could redefine medicine and offer new hope for cancer, autoimmune diseases, and neurological disorders through advanced CAR-NK therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.

Review top news and interview highlights from the week ending December 13, 2024.

The results come from patients with lenalidomide-refractory MM treated in the CARTITUDE-4 trial after 1 to 3 lines of prior therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A long-term follow-up to the DREPAGREFFE-1 trial suggest that children with sickle cell anemia may benefit long-term on risk of cerebral injury, cognitive functions, and quality of life over standard care transfusions.

Among those who had undetectable minimal residual disease, autologous hematopoietic cell transplantation showed signs of benefit only for those who remained MRD-positive following induction therapy.